# NIH Reporter #5U54CA274321-05

Quantification of cisplatin sensitivity and resistance using metabolic imaging and circulating tumor cell (CTC) biomarkers

**Recipient:** University of TX MD Anderson Cancer Center

**Award Amount:** $232,073.00
**Ceiling:** $232,073.00

**Awarded:** September 08, 2026

**Identifier:** 5U54CA274321-05

NIH awarded $232,073 to University of TX MD Anderson Cancer Center for research on using HP-MRI and CTC biomarkers to predict cisplatin sensitivity and resistance in cancer treatment, aiming to improve precision oncology.

### Description

This project focuses on assessing tumor response with minimally invasive imaging (hyperpolarized magnetic resonance imaging; HP-MRI) and detection of biological shifts in circulating tumor cells (CTCs) during cisplatin-based therapy to validate biomarkers and optimize treatment for head and neck squamous cell carcinoma (HNSCC).

[View original record](https://reporter.nih.gov/search/0C83gI3MXki4-tEhFD4UKQ/project-details/11416342)